Dailymed elahere
WebNov 20, 2024 · Elahere is a first-in-class antibody-drug conjugate directed against FRα, a cell-surface protein highly expressed in ovarian cancer. The antibody is a chimeric IgG1 directed against FRα. The small molecule, DM4, is a microtubule inhibitor designed to kill the targeted cancer cells. It is attached to the antibody via a cleavable linker. WebMar 1, 2024 · ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer …
Dailymed elahere
Did you know?
WebAt the Howard Hughes Medical Institute, we believe in the power of individuals to advance science through research and science education, making discoveries that benefit … WebConnect with an ELAHERE Support Services Program specialist. Phone: 1-833-ELAHERE. ( 1-833-352-4373 ) Monday to Friday, 8:00 am to 8:00 pm ET. Email: [email protected]. BACK TO TOP. …
WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and. have received 1 to 3 prior types of chemotherapy. WebThe safety of Elahere has been evaluated in a pooled analysis from three studies among a total of 464 patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received at least one dose of Elahere (6 mg/kg adjusted ideal body weight (AIBW) administered intravenously once every 3 weeks).
WebELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ... DailyMed will deliver this ... WebELAHERE is an ADC that binds to tumor surface receptor FRα. Upon binding to the FRα receptor, ELAHERE is internalized into the cell. This prompts intracellular release of DM4, a potent cytotoxic tubulin inhibitor, resulting in cell death. DM4 diffuses across the cell membrane and kills neighboring cells (bystander killing)†.
WebNov 15, 2024 · Published on: November 15, 2024. Brielle Benyon. The FDA approved Elahere for patients with pretreated, folate receptor alpha (FRα)-positive platinum-resistant gynecological cancers. The Food and Drug Administration (FDA) granted an accelerated approval to Elahere (mirvetuximab soravtansine-gynx) for the treatment of patients with …
WebThe Daily Medic - Stickers and merch for EMS, Fire, and Medical. Firefighter / Paramedic Owned. Free Shipping over $35. green compound pharmacyWebELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum … green compoundsWebMar 1, 2024 · Elahere Injection Dosage and Administration Patient Selection. Select patients for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with ELAHERE … flow-tech meter services ltdWebElahere (mirvetuximab sorvtansine-gynx) Requests for Elahere (mirvetuximab sorvtansine-gynx) may be approved if the following criteria are met: I. Individual has a diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; flowtech mechanical keyboardWebELAHERE Support Services is committed to helping appropriate patients start on ELAHERE by offering access and reimbursement support as well as affordability assistance. For more information, call the ELAHERE Support Services Program at 1-833-ELAHERE (1-833-352-4373) Monday to Friday, 8:00 am to 8:00 pm ET ELAHERE BILLING AND CODING GUIDE flowtech mufflers catalogWebDec 2, 2024 · Elahere can cause serious side effects, including: Eye problems. Eye problems are common with Elahere and can also be severe. Tell your healthcare provider right away if you develop any eye problems during treatment with Elahere, including blurred vision, dry eyes, sensitivity to light, eye pain, or new or worsening vision changes. green compression shortsWebNov 15, 2024 · ImmunoGen announces FDA accelerated approval of Elahere™ (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. News release. ImmunoGen. November 14, 2024 ... green compound riyadh